Wedbush raised the firm’s price target on Kura Oncology (KURA) to $38 from $36 and keeps an Outperform rating on the shares. The firm notes Ziftomenib at 600 mg QD dosing was approved in r/r NPM1m AML, ahead of the PDUFA date of November 30th. The approval was based on the KOMET-001 study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA: